Botanix Pharmaceuticals (ASX: BOT) has announced that its chief operating officer has been appointed as its chief executive officer.
Dr McKibbon was also previously the chief commercial officer for Botanix, and this new promotion reflects both his extensive 25-year experience in the pharmaceutical industry.
Executive chairman Vince Ippolito said, “I am very pleased to congratulate Howie on his promotion to CEO and the opportunity that Botanix presents for him and our shareholders at this exciting time. I have had the pleasure of working with Howie in three different dermatology companies before Botanix and I can think of no one better qualified or capable to lead us through this next stage of the company’s growth, for the commercial launch of Sofpironium Bromide and rapid expansion of the company’s operations and revenue generation. His experience and proven track record of success is unsurpassed in medical dermatology and I look forward to working with him in his new role at Botanix.”
Dr McKibbon is based in Arizona, where Botanix has recently expanded its commercial operations.
Dr McKibbon previously held senior executive roles with Dermavant Science, Anacor Pharmaceuticals, and Medicis Pharmaceuticals.
Over the course of his career, Dr McKibbon has launched more than 15 branded products, managed over thirty dermatology products, and played a significant role in two of the largest dermatology acquisitions with combined valuations of US$7.8 billion.
Dr McKibbon said, “It’s a privilege to be appointed CEO of Botanix and to assume responsibility for the development of the Company at such an exciting time. Having worked closely with Vince for more than 13 years and the Botanix board and team for almost five years now, I have a clear vision for the future of the Company and am excited about building Botanix into the world’s most successful independent dermatology company.”